Latest Breaking News On - Rupert pearse - Page 7 : vimarsana.com
Dread and anxiety among NHS staff as Covid cases surge again | NHS
theguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theguardian.com Daily Mail and Mail on Sunday newspapers.
Dread and anxiety among NHS staff as Covid cases surge again
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Advertisement
Almost half of all over-50s in England have now been fully vaccinated against coronavirus and as many as two-thirds have been covered in parts of the country leading the way, the latest official figures show.
About 10.5million people in the age group had received both vaccine doses across England by May 2 a rate of 47 per cent according to NHS statistics.
But, as has been the case throughout the rollout, analysis by MailOnline shows uptake has varied.
Some 93 of England s 315 local authorities have already seen more than half of their over-50 populations receive a top-up shot but in 26 areas it is fewer than four in 10 and in two authorities the rate is below 30 per cent.
Virginia Mayo/AP/Shutterstock
Vaccines from Johnson & Johnson and Novavax report positive trial results
A coronavirus vaccine developed by the US firm Novavax has been shown to be 89 per cent effective in preventing covid-19 in clinical trials. The trials included participants in the UK and South Africa, and found the vaccine to be 86 per cent effective against the UK variant of the virus, but only 60 per cent effective against the variant in South Africa. Novavax said it will immediately begin development on a vaccine specifically targeted to the South African variant.
Advertisement
Janssen, a subsidiary of US firm Johnson & Johnson, announced that its covid-19 vaccine showed 66 per cent efficacy in an international trial. These results are based on a single dose of the vaccine, which makes it easier to administer than the two-shot vaccines that have already been approved. The company has said it will sell its vaccine on a not-for-profit basis.
vimarsana © 2020. All Rights Reserved.